INTERFACE BIOLOGICS, INC. (IBI) is a privately held early commercial stage company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices. Our primary technology focus areas are anti-thrombogenic additives that reduce thrombosis and programmable combination drug delivery devices. The name, Interface Biologics, comes from the critical interface between the human body and medical devices at the molecular level. (BIOTECanada)(LSO)